看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
) N2 w3 x! }0 t4 @ r' R) W6 w M6 l4 ~, \
% y& H- V8 Z2 F" o8 lCurrently available feasibility data for possible combination strategies.
8 f. ]( a6 O. u———————————————————————————————— L: E0 X/ G* U; `7 i4 M
Combination Feasibility according to preliminary data
8 k: ]; Y4 x8 E2 ]——————————————————————————————————! s' X1 y, F6 U8 ]# _, \2 N" A
Bevacizumab + sorafenib Yes, reduced dose / n4 {$ T+ i1 d( B. d) ]
Bevacizumab + sunitinib† No
, D9 Y4 v: \2 u& ?- [& c7 Q5 |Bevacizumab + temsirolimus Yes " |) y* N3 B9 R/ v" ^
Bevacizumab + everolimus Yes * T9 ^8 ]9 O! g+ |: _9 E
Sorafenib + sunitinib ? 0 c' U5 h/ P0 i6 ^, w9 B
Sorafenib + temsirolimus Yes, reduced dose
( S' m0 t6 Z4 v& BSorafenib + everolimus Yes, reduced dose
5 A( Q. s: v8 Q, ]9 PSunitinib + temsirolimus† No
4 H$ z/ J9 x6 }2 O6 q8 LSunitinib + everolimus ?
0 A( G9 r9 Q3 B# DTemsirolimus + everolimus ?
' a' D0 L7 V9 O6 V0 D0 }- f1 z" V————————————————————
7 o( m* @* f8 l- L†Led to US FDA warning.2 \" o" V0 n% I$ D# ? T! Q" ]
?: As yet unattempted combination.7 V5 x( _8 x0 t2 m1 c- ~; b, ?* f; K
|